L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use ...

YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Polymyositis.

ULSCs is under clinical development by RESTEM and currently in Phase I for Dermatomyositis. According to GlobalData, Phase I drugs for Dermatomyositis have a 91% phase transition success rate (PTSR) ...

Inflammatory Myositis Overview Myositis refers to muscle inflammation and is commonly associated with inflammatory myopathies, including polymyositis, dermatomyositis, cancer-associated myositis ...

Melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM) is a rare systemic autoimmune disease associated with a high rate of mortality attributable to rapidly progressive ...

Gottron papules are red or violet bumps that form on the outside joints of the hand. They are caused by a rare inflammatory muscle disease called dermatomyositis. In addition to classic skin changes, ...

Polymyositis is an autoimmune disease that causes inflammation and weakness of the skeletal muscles responsible for movement. Dermatomyositis is a form of polymyositis that is associated with skin ...

Internal organs, including the skin, joints, lungs, heart, and gastrointestinal tract, can also be affected in both skin-dominant [dermatomyositis (DM)] and muscle-dominant forms [polymyositis (PM)] ...

- Oral presentation at ACR highlights safety and efficacy data from the Phase 1 trial of umbilical cord outer lining-derived stem cells (ULSCs) in patients with ...